GlassScriptPhysician profile
Jitlada Lapma Austin
NPI 1730743345
$5,074.14
in general payments reported to CMS, 2019-2025
48 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,793 · 2022: $2,493 · 2023: $691 · 2024: $53.33 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.16 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $525.57 | 2021-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $356.09 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $330.34 | 2021-2023 | Padcev, Tukysa |
| Merck Sharp & Dohme LLC | $279.21 | 2021-2022 | |
| Janssen Biotech, INC. | $275.86 | 2021-2023 | Erleada, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $264.15 | 2021-2023 | Ninlaro |
| Astellas Pharma US INC | $253.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $236.14 | 2021-2023 | |
| Eisai INC. | $218.90 | 2021-2024 | |
| Celgene Corporation | $204.99 | 2022-2023 | Reblozyl, Opdualag |
| Lilly USA, LLC | $203.22 | 2021-2023 | Retevmo, Verzenio |
| Myovant Sciences INC. | $190.29 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $183.14 | 2021-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $172.65 | 2021-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $144.54 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitlada Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.